OPNT
Income statement / Annual
Last year (2021), Opiant Pharmaceuticals, Inc.'s total revenue was $40.73 M,
an increase of 48.62% from the previous year.
In 2021, Opiant Pharmaceuticals, Inc.'s net income was $3.01 M.
See Opiant Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
07/31/2017 |
07/31/2016 |
07/31/2015 |
07/31/2014 |
07/31/2013 |
07/31/2012 |
| Operating Revenue |
$40.73 M |
$27.40 M |
$38.24 M |
$13.51 M |
$18.45 M |
$9.90 M |
$1.55 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$9.07 M
|
$6.20 M
|
$7.72 M
|
$1.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$31.66 M
|
$21.21 M
|
$30.52 M
|
$12.02 M
|
$18.45 M
|
$9.90 M
|
$1.55 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.78
|
0.77
|
0.8
|
0.89
|
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$16.83 M
|
$9.24 M
|
$9.08 M
|
$8.48 M
|
$3.17 M
|
$1.75 M
|
$2.42 M
|
$464.61 K
|
$282.67 K
|
$506.17 K
|
| General & Administrative Expenses |
$12.15 M
|
$11.74 M
|
$12.20 M
|
$11.26 M
|
$6.53 M
|
$15.57 M
|
$6.04 M
|
$10.84 M
|
$4.00 M
|
$11.83 M
|
| Selling & Marketing Expenses |
$4.58 M
|
$4.69 M
|
$611.57 K
|
$213.90 M
|
$1.65 M
|
$317.92 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.73 M
|
$16.43 M
|
$12.81 M
|
$11.48 M
|
$8.18 M
|
$15.89 M
|
$6.04 M
|
$10.84 M
|
$4.00 M
|
$11.83 M
|
| Other Expenses |
-$7.06 M
|
-$2.22 M
|
-$2.28 M
|
$13.26 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.50 M
|
$23.45 M
|
$19.61 M
|
$33.21 M
|
$11.35 M
|
$17.64 M
|
$8.45 M
|
$11.30 M
|
$4.29 M
|
$12.34 M
|
| Cost And Expenses |
$35.57 M
|
$29.64 M
|
$27.33 M
|
$34.70 M
|
$11.35 M
|
$17.64 M
|
$8.45 M
|
$11.30 M
|
$4.29 M
|
$12.34 M
|
| Interest Income |
$11.40 K
|
$93.88 K
|
$437.65 K
|
$0.00
|
$23.68 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$2.13 M
|
$131.01 K
|
$0.00
|
$0.00
|
$3.72 K
|
$11.89 K
|
$28.23 K
|
$160.30 K
|
$553.05 K
|
$61.39 K
|
| Depreciation & Amortization |
$661.53 K
|
$608.47 K
|
$237.79 K
|
$2.56 K
|
$5.14 K
|
$2.39 K
|
$1.37 K
|
$1.37 K
|
$1.37 K
|
$1.37 K
|
| EBITDA |
$5.83 M |
-$1.55 M |
$11.15 M |
-$21.14 M |
$7.14 M |
-$7.80 M |
-$7.01 M |
-$11.32 M |
-$4.10 M |
-$12.36 M |
| EBITDA Ratio |
0.14
|
-0.06
|
0.29
|
-1.56
|
0.39
|
-0.79
|
-4.52
|
0
|
0
|
0
|
| Operating Income Ratio |
0.13
|
-0.08
|
0.29
|
-1.57
|
0.38
|
-0.78
|
-4.45
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.12 M
|
-$8.98 K
|
$66.68 K
|
$46.41 M
|
$38.32 K
|
-$75.78 K
|
-$138.00 K
|
-$179.00 K
|
-$371.00 K
|
-$85.48 K
|
| Income Before Tax |
$3.03 M
|
-$2.29 M
|
$11.42 M
|
-$21.14 M
|
$7.13 M
|
-$7.81 M
|
-$7.04 M
|
-$11.48 M
|
-$4.66 M
|
-$12.42 M
|
| Income Before Tax Ratio |
0.07
|
-0.08
|
0.3
|
-1.56
|
0.39
|
-0.79
|
-4.54
|
0
|
0
|
0
|
| Income Tax Expense |
$24.27 K
|
-$426.00 K
|
-$177.00 K
|
$51.28 K
|
$550.47 K
|
-$52.00 K
|
$0.00
|
$0.00
|
$0.00
|
$37.30 K
|
| Net Income |
$3.01 M
|
-$1.86 M
|
$11.59 M
|
-$21.20 M
|
$6.58 M
|
-$7.81 M
|
-$7.04 M
|
-$11.48 M
|
-$4.66 M
|
-$12.42 M
|
| Net Income Ratio |
0.07
|
-0.07
|
0.3
|
-1.57
|
0.36
|
-0.79
|
-4.54
|
0
|
0
|
0
|
| EPS |
0.68 |
-0.44 |
2.88 |
-7.1 |
3.27 |
-4.09 |
-3.88 |
-6.57 |
-3.25 |
-11.96 |
| EPS Diluted |
0.51 |
-0.44 |
2.17 |
-7.1 |
2.94 |
-4.09 |
-3.88 |
-6.57 |
-3.25 |
-11.96 |
| Weighted Average Shares Out |
$4.46 M
|
$4.25 M
|
$4.02 M
|
$2.99 M
|
$2.02 M
|
$1.91 M
|
$1.81 M
|
$1.75 M
|
$1.43 M
|
$1.04 M
|
| Weighted Average Shares Out Diluted |
$5.92 M
|
$4.25 M
|
$5.34 M
|
$2.99 M
|
$2.24 M
|
$1.91 M
|
$1.81 M
|
$1.75 M
|
$1.43 M
|
$1.04 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
